The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer

Journal of Clinical Gastroenterology

Volumn 39, Issue 1, 2005, Pages 50-55

  Wu, Chun Ying ^a,c,d   Wu, Ming Sing ^b   Chen, Chien Jen ^a   Li, Mu Chun ^c   Lin, Jaw Town ^b,e   Chen, Gran Hum ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cyclooxygenase 2; Gastric ulcer; Helicobacter pylori; Nonsteroidal anti inflammatory drugs

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG USE; ENDOSCOPIC BIOPSY; FEMALE; GIEMSA STAIN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUESTIONNAIRE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ANTRUM; STOMACH MUCOSA; STOMACH ULCER; ULCER HEALING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYLORIC ANTRUM; RNA, MESSENGER; STOMACH ULCER;

EID: 11144327182     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000;119:521-535.
2. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22.
3. Peterson WL. Helicobacter pylori. In: Feldman M, ed. Gastrointestinal and Liver Diseases: Pathophysiology/Diagnosis/Management. Philadelphia: Saunders, 1998:604-619.
4. Cryer B. Non-steroidal anti-inflammation drugs and gastrointestinal diseases. In: Feldman M, ed. Gastrointestinal and Liver Diseases: Pathophysiology/Diagnosis/Management. Philadelphia: Saunders, 1998:343-356.
5. Hunt RH, Sumanac K, Huang JQ. Review article: should we kill or should we save Helicobacter pylori? Aliment Pharmacol Ther. 2001;15(suppl 1):51-59.
6. Wu CY, Poon SK, Chen GH, et al. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol. 1999;34:234-237.
7. Chan FK. Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Gastroenterol Clin North Am. 2001;30:937-952.
8. Bianchi PG, Parente F, Imbesi V, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut. 1996;39:22-26.
9. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975-979.
10. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study: Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016-1021.
11. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.
12. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266.
13. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190:279-286.
14. Zarrilli R, Ricci V, Romano M. Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol. 1999;1:93-99.
15. Ishihara S, Fukuda R, Kawashima K, et al. T cell-mediated cytotoxicity via Fas/Fas ligand signaling in Helicobacter pylori-infected gastric corpus. Helicobacter. 2001;6:283-293.
16. Moss SF, Sordillo EM, Abdalla AM, et al. Increased gastric epithelial cell apoptosis associated with colonization with caga + Helicobacter pylori strains. Cancer Res. 2001;61:1406-1411.
17. McCarthy CJ, Crofford LJ, Greenson J, et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:1218-1223.
18. Kim H, Lim JW, Kim KH. Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by nuclear factor-kappaB. Scand J Gastroenterol. 2001;36:706-716.
19. Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut. 2000;46:782-789.
20. To KF, Chan FK, Cheng AS, et al. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther. 2001;15:25-34.
21. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112:387-397.
22. Brzozowski T, Konturek PC, Konturek SJ, et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech. 2001;53:343-353.
23. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis: the updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
24. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 1999;45:1148-1156.
25. Bismar TA, Bianco FJ, Zhang H, et al. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Pathology. 2003;35:513-517.
26. Fischer H, Huber V, Boknik P, et al. Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans. Microsc Res Tech. 2001;53:336-342.
27. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 1999;116:1319-1329.
28. Takahashi M, Katayama Y, Takada H, et al. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther. 2000; 14(suppl 1):44-49.
29. Tseng GY, Lin HJ, Lin HY, et al. Effect of non-steroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection. Hepatogastroenterology. 1999;46:1000-1004.
30. Peskar BM. Role of cyclooxygenase isoforms in gastric mucosal defence. J Physiol (Paris). 2001;95:3-9.